Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of G1 Therapeutics Inc (NASDAQ: GTHX) closed at $4.98 in the last session, up 16.08% from day before closing price of $4.29. In other words, the price has increased by $16.08 from its previous closing price. On the day, 34.33 million shares were traded. GTHX stock price reached its highest trading level at $6.14 during the session, while it also had its lowest trading level at $4.28.
Ratios:
We take a closer look at GTHX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.55 and its Current Ratio is at 2.94. In the meantime, Its Debt-to-Equity ratio is 1.70 whereas as Long-Term Debt/Eq ratio is at 1.48.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 30, 2023, Upgraded its rating to Neutral and sets its target price to $10 from $7 previously.
On January 03, 2023, Needham reiterated its Buy rating and also upped its target price recommendation from $32 to $31.
JP Morgan Downgraded its Neutral to Underweight on November 04, 2021, whereas the target price for the stock was revised from $20 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 18 ’24 when Umstead John W. V sold 6,547 shares for $3.02 per share. The transaction valued at 19,752 led to the insider holds 123,896 shares of the business.
Malik Rajesh sold 28,600 shares of GTHX for $132,143 on Feb 12 ’24. The Chief Medical Officer now owns 169,938 shares after completing the transaction at $4.62 per share. On Jan 04 ’24, another insider, MURDOCK TERRY L, who serves as the Chief Operating Officer of the company, sold 721 shares for $2.94 each. As a result, the insider received 2,121 and left with 103,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GTHX now has a Market Capitalization of 260361376 and an Enterprise Value of 206190160. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.10 while its Price-to-Book (P/B) ratio in mrq is 9.38. Its current Enterprise Value per Revenue stands at 2.453 whereas that against EBITDA is -9.235.
Stock Price History:
The Beta on a monthly basis for GTHX is 1.77, which has changed by 0.5376344 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, GTHX has reached a high of $5.00, while it has fallen to a 52-week low of $1.08. The 50-Day Moving Average of the stock is 23.97%, while the 200-Day Moving Average is calculated to be 85.40%.
Shares Statistics:
According to the various share statistics, GTHX traded on average about 1.13M shares per day over the past 3-months and 593160 shares per day over the past 10 days. A total of 51.93M shares are outstanding, with a floating share count of 42.45M. Insiders hold about 18.81% of the company’s shares, while institutions hold 22.85% stake in the company. Shares short for GTHX as of 1713139200 were 2421729 with a Short Ratio of 2.14, compared to 1710460800 on 2694597. Therefore, it implies a Short% of Shares Outstanding of 2421729 and a Short% of Float of 4.67.
Earnings Estimates
Its stock is currently analyzed by 6.0 different market analysts. On average, analysts expect EPS of -$0.17 for the current quarter, with a high estimate of -$0.15 and a low estimate of -$0.19, while EPS last year was $0.14. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.35 and -$0.64 for the fiscal current year, implying an average EPS of -$0.55. EPS for the following year is -$0.31, with 6.0 analysts recommending between -$0.1 and -$0.65.
Revenue Estimates
According to 6 analysts, the current quarter’s revenue is expected to be $16.45M. It ranges from a high estimate of $18.54M to a low estimate of $15.29M. As of the current estimate, G1 Therapeutics Inc’s year-ago sales were $42.39MFor the next quarter, 6 analysts are estimating revenue of $18.17M. There is a high estimate of $21.75M for the next quarter, whereas the lowest estimate is $15.72M.
A total of 6 analysts have provided revenue estimates for GTHX’s current fiscal year. The highest revenue estimate was $80M, while the lowest revenue estimate was $61.69M, resulting in an average revenue estimate of $72.76M. In the same quarter a year ago, actual revenue was $82.51MBased on 6 analysts’ estimates, the company’s revenue will be $99.09M in the next fiscal year. The high estimate is $116.11M and the low estimate is $67.9M.
